Construction of a TTN Mutation-Based Prognostic Model for Evaluating Immune Microenvironment, Cancer Stemness, and Outcomes of Colorectal Cancer Patients

Figure 6

ISS as a predictor of tumor immune status and immunotherapy responsiveness: (a) correlation between the ISS and ISS component genes and tumor mutation burden and immune features; (b) comparison of ISS between different immune cell groups; (c) comparison of ISS between different immune subtypes; (d) comparison of immunotherapy responsiveness between the high- and low-ISS groups; (e) comparison of patient prognosis between the high- and low-ISS groups.

(a)

(b)

(c)

(d)

(e)